Clinical Trial Update: A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combo of Daratumumab plus Durvalumab in relapsed and refractory multiple myeloma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Durvalumab (durvalumab)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2018-10-16